Overview

Staccato Loxapine in Agitated Patients With Bipolar Disorder

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in bipolar 1 disorder patients.
Phase:
Phase 3
Details
Lead Sponsor:
Alexza Pharmaceuticals, Inc.
Treatments:
Loxapine